interleukin 1beta (193-195) has been researched along with Inflammatory Bowel Diseases in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bednarz-Misa, I; Kapturkiewicz, B; Krzystek-Korpacka, M; Neubauer, K; Zacharska, E | 1 |
1 other study(ies) available for interleukin 1beta (193-195) and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
Whole blood ACTB, B2M and GAPDH expression reflects activity of inflammatory bowel disease, advancement of colorectal cancer, and correlates with circulating inflammatory and angiogenic factors: Relevance for real-time quantitative PCR.
Topics: Actins; Angiogenesis Inducing Agents; beta 2-Microglobulin; Biomarkers, Tumor; Chemokine CCL4; Colorectal Neoplasms; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating); Humans; Inflammatory Bowel Diseases; Interleukin-1beta; Peptide Fragments; Real-Time Polymerase Chain Reaction; Reference Standards | 2020 |